advertisement
Abstract #9851 Published in IGR 5-3
The effect of intravitreal triamcinolone acetonide on intraocular pressure
Bakri SJ; Beer PMOphthalmic Surgery Lasers and Imaging 2003; 34: 386-390
BACKGROUND AND OBJECTIVE: To ascertain whether a single 4-mg intravitreal triamcinolone acetonide injection is associated with elevated intraocular pressure (IOP). PATIENTS AND METHODS: Retrospective noncomparative interventional case series. Forty-three consecutive eyes of 38 patients who had 12 weeks of follow-up were included. The IOPs before and after triamcinolone acetonide treatment were recorded by Goldmann applanation at each patient visit. RESULTS: Within 12 weeks after intravitreal triamcinolone acetonide injection, 21 of 43 eyes (48.8%) demonstrated an increase in IOP of 5 mmHg or greater, and 12 of 43 eyes (27.9%) had an increase in IOP of 10 mmHg or greater. The mean time for an increase in IOP of 5 mmHg or greater to occur was 4.1 weeks (standard deviation = 4.8 weeks), and the mean time to reach maximum IOP was 6. 6 weeks (standard deviation = 5.1). The difference between the mean pre-injection IOP (15.12 mmHg, n = 43) and the maximum post-injection IOP (20.74 mmHg, n = 43) was statistically significant (p < 0.0001). CONCLUSIONS: A single 4-mg intravitreal triamcinolone acetonide injection is associated with an increase in IOP of 10 mmHg or greater in 27.9% of eyes after the first injection. All eyes responded to topical glaucoma medication.
Dr. P.M. Beer, Lions Eye Institute, Albany Medical College, 35 Hackett Boulevard, Albany, NY 12208, USA
Classification:
9.4.1 Steroid-induced glaucoma (Part of: 9 Clinical forms of glaucomas > 9.4 Glaucomas associated with other ocular and systemic disorders)
